現在価格
目標株価
アナリスト評価
5 評価: 買い
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
e.g. Promoter holding
Loading chart...
アナリストによるEPSおよび売上高の予想コンセンサス。
| Metric (B) | FY 2025 | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.96 | $-1.10 | $-1.26 | $-1.05 | $-0.64 | $-0.63 | $-3.87 | $-4.90 | $-1.43 | $-5.96 | |
| 0 | 0 | 0 | 0 | 0 | 0.01 | 0.04 | 0.02 | 0 | 0 | |
| -0.7% | +6.5% | -0.5% | — | — | +6.0% | +15.1% | +1.2% | +28.0% | +26.1% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TTevogen Bi... | TVGN | $406.59M | — | — | — | — | — | — |
| 2. | OOutlook Th... | OTLK | $100.54M | — | 38.42 | — | 4,782.00% | -3.65% | -99.40% |
| 3. | IInvivyd In... | IVVD | $171.58M | — | 0.95 | -183.90% | -192.80% | -95.90% | 21.20% |
| 4. | MMediWound... | MDWD | $185.63M | — | 5.20 | -235.00% | -337.60% | -57.40% | -34.20% |
| 5. | VVanda Phar... | VNDA | $241.27M | — | 1.21 | -119.90% | -77.60% | -82.60% | 24.10% |
連結数値(百万円)/単体表示可
| Quarter (M) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 2.34 | 2.97 | 1.57 | 3.85 | 12.47 | 0.86 | 19.64 | 3 |
COGS | 0.71 | 0.74 | 0 | 138.13 | 0 | 1.5 | 0.15 | 0.34 |
Gross Profit | 2.34 | 2.97 | 1.57 | -134.28 | 12.47 | -0.64 | 19.48 | 2.66 |
Gross Profit % | 100% | 100% | 100% | -3490.46% | 100% | -73.95% | 99.23% | 88.58% |
| 100.47 | 123.96 | 133.09 | 36.86 | 201.28 | 253.84 | 36.76 | 25.28 | |
EBIT | -98.13 | -120.99 | -131.52 | -171.14 | -188.81 | -254.48 | -17.28 | -22.62 |
OPM % | -4200.94% | -4069.63% | -8360.9% | -4448.71% | -1513.47% | -29590.47% | -88.01% | -752.93% |
Non-Operating Income | 17.74 | 18.73 | 15.74 | 13.83 | 14.36 | 17.38 | 0.65 | 2.43 |
PBT | -80.4 | -102.26 | -115.77 | -157.31 | -174.44 | -237.1 | -16.63 | -20.19 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -80.4 | -102.26 | -115.77 | -157.31 | -174.44 | -237.1 | -16.63 | -20.19 |
NPM % | -3441.7% | -3439.52% | -7360.01% | -4089.29% | -1398.33% | -27569.88% | -84.71% | -671.97% |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2012 | Dec 2013 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 10.36 | 13.09 | 0.38 | 2.32 | 6.79 | 9.33 | 9.22 | 9.56 | 10.9 | 18.75 |
COGS | 22.75 | 32.51 | 8.44 | 14.54 | 37.6 | 0.64 | 1.39 | 2.1 | 2.78 | 4.15 |
Gross Profit | 0 | 0 | -8.06 | 2.32 | 6.79 | 9.33 | 9.22 | 7.46 | 10.9 | 14.6 |
Gross Profit % | - | - | -2125.86% | 100% | 100% | 100% | 100% | 78.02% | 100% | 77.87% |
| 18.98 | 25.44 | 10.88 | 19.65 | 51.06 | 127.38 | 188.14 | 243.06 | 389.83 | 760.55 | |
EBIT | 0 | 0 | -10.5 | -17.33 | -44.28 | -118.05 | -178.91 | -235.6 | -378.94 | -745.94 |
OPM % | - | - | -2769.92% | -747.39% | -652.38% | -1265.83% | -1939.65% | -2464.41% | -3477.43% | -3977.3% |
Non-Operating Income | 0 | 0 | -0.72 | -7.4 | -0.08 | 0.04 | 4.92 | 23.38 | 56.63 | 61.31 |
PBT | 0 | 0 | -11.22 | -24.73 | -44.35 | -118.01 | -174 | -212.22 | -322.3 | -684.63 |
Income Tax | 0 | 0 | 0.72 | 7.39 | -0.37 | -0.64 | -4.92 | 1.93 | 0 | 0 |
Tax Rate % | - | - | -6.4% | -29.87% | 0.84% | 0.54% | 2.83% | -0.91% | - | - |
Net Income | 0 | 0 | -11.93 | -24.73 | -43.98 | -117.37 | -169.08 | -212.22 | -322.3 | -684.63 |
NPM % | - | - | -3148.81% | -1066.58% | -648.03% | -1258.52% | -1833.01% | -2219.87% | -2957.71% | -3650.39% |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2012 | Dec 2013 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 53.72 | 113.31 | 3.09 | 94.58 | 328.14 | 320.45 | 340.4 | 185.08 | 219.87 | 382.52 | |
| 0 | 0 | 0 | 0 | 6.68 | 85.09 | 270.33 | 410.27 | 1,281.63 | 1,314.35 | |
| 3.19 | 3 | 0.7 | 0.63 | 1.92 | 15.59 | 15.01 | 0 | 0 | 0 | |
| 0.38 | 1.28 | 0.3 | 1.9 | 3.54 | 4.7 | 12.22 | 8.62 | 40.79 | 101.6 | |
| 5.12 | 7.51 | -0.11 | -0.2 | -6.38 | 1.75 | 0.85 | 24.58 | 21.61 | 159.58 | |
Total Assets | 62.41 | 125.1 | 3.98 | 96.91 | 333.9 | 427.58 | 638.8 | 628.55 | 1,563.89 | 1,958.05 |
| 0.38 | 0.49 | 0.43 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| 20.15 | 86.6 | -41.55 | -65.36 | 306.22 | 381.43 | 578.07 | 500.76 | 1,424.95 | 1,688.59 | |
| 8.17 | 10.51 | 10.32 | 4.94 | 0.94 | 11.73 | 10.69 | 9.85 | 6.8 | 94.56 | |
| 15.62 | 12.24 | 1.87 | 3.62 | 18.64 | 27.89 | 43.76 | 48.68 | 73.19 | 169.87 | |
| 18.08 | 15.25 | 32.92 | 153.71 | 8.1 | 6.53 | 6.28 | 69.26 | 58.95 | 5.02 | |
Total Liabilities | 62.41 | 125.1 | 3.98 | 96.91 | 333.9 | 427.58 | 638.8 | 628.55 | 1,563.89 | 1,958.05 |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2012 | Dec 2013 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | -9.65 | 2.49 | -37.12 | -94.81 | -136.27 | -119.06 | -300.87 | -650.44 | |
| 0 | 0 | -0.05 | -0.23 | -7.79 | -82.52 | -189.96 | -130.07 | -854.2 | -38.03 | |
| 34.32 | 88.02 | 5.14 | 89.23 | 272.04 | 176.32 | 346.17 | 93.86 | 1,192.36 | 850.99 | |
Net CFNet Cash Flow | 34.32 | 88.02 | -4.56 | 91.49 | 227.13 | -1.01 | 19.95 | -155.27 | 37.29 | 162.51 |
FCFFree Cash Flow | 0 | 0 | -9.7 | 2.25 | -38.21 | -98.55 | -139.09 | -123.29 | -307.94 | -663.76 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2012 | Dec 2013 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -51.9% | 46.5% | -36.5% | -34.1% | -35.2% | -39.3% | -33.5% | -44.0% | |
| 0.40 | 0.12 | -0.25 | -0.08 | 0.00 | 0.03 | 0.02 | 0.02 | 0.00 | 0.06 | |
| - | - | 0.70 | 9.35 | 22.74 | 13.86 | 12.00 | 7.58 | 15.73 | 9.20 | |
| 0.22 | 0.14 | 0.01 | 0.05 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
Cash Conversion | - | - | 0.81 | -0.10 | 0.84 | 0.81 | 0.81 | 0.56 | 0.93 | 0.95 |
Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| -8.1% | 26.4% | -97.1% | 511.9% | 192.7% | 37.4% | -1.1% | 3.6% | 14.0% | 72.1% | |
| - | - | -0.32 | -0.66 | -1.17 | -2.48 | -2.95 | -2.79 | -2.49 | -5.30 | |
| - | - | - | - | -20.76 | -8.30 | -6.58 | -3.46 | -12.23 | -13.60 | |
| 0.00 | 1.00 | 2.00 | 7.00 | 4.00 | 3.00 | 3.00 | 3.00 | 5.00 | 3.00 | |
| -2.44 | -2.05 | -18.41 | -10.90 | -1.19 | -2.19 | 0.11 | 5.48 | -0.90 | -0.68 | |
| 80.00 | 100.00 | 0.00 | 100.00 | 66.67 | 66.67 | 66.67 | 66.67 | 66.67 | 66.67 | |
| - | - | -31.5% | -10.7% | -6.5% | -12.6% | -18.3% | -22.2% | -29.6% | -36.5% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Avidity Biosciences Incの株主構成(SEC提出書類より)
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| Shares held | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|
InsidersInsiders | 0 | 0 | 0 |
| 1.5M | 1.4M | -91.8K | |
| 13.2M | 13.9M | +640.0K | |
| 82.1K | 193.3K | +111.1K | |
No. of institutional holders | 160 | 153 | -7 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 3,749,186 | +0.6% | 16.07 | |
| 15 Oct 2026 | 3,726,302 | +9.7% | 12.94 | |
| 30 Sep 2026 | 3,395,873 | -0.1% | 8.27 | |
| 15 Sep 2026 | 3,397,791 | +1.4% | 8.15 | |
| 31 Aug 2026 | 3,351,526 | -3.7% | 19.79 | |
| 14 Aug 2026 | 3,480,849 | -0.9% | 27.46 | |
| 31 Jul 2026 | 3,514,133 | -2.1% | 28.39 | |
| 15 Jul 2026 | 3,591,224 | -1.8% | 17.71 | |
| 30 Jun 2026 | 3,656,821 | +1.3% | 12.52 | |
| 15 Jun 2026 | 3,610,418 | -1.2% | 20.31 | |
| 29 May 2026 | 3,653,605 | -2.1% | 15.83 | |
| 15 May 2026 | 3,732,204 | +8.9% | 21.18 | |
| 30 Apr 2026 | 3,425,955 | +13.6% | 8.71 | |
| 15 Apr 2026 | 3,016,880 | +57.6% | 6.00 | |
| 31 Mar 2026 | 1,913,700 | +61.5% | 2.90 | |
| 13 Mar 2026 | 1,184,615 | +173.7% | 1.00 | |
| 27 Feb 2026 | 432,798 | 1.00 | ||
| 13 Feb 2026 | 10,156,722 | +16.1% | 3.56 | |
| 30 Jan 2026 | 8,745,197 | +4.0% | 6.35 | |
| 15 Jan 2026 | 8,406,349 | -4.4% | 4.20 | |
| 31 Dec 2025 | 8,791,796 | -9.7% | 4.61 | |
| 15 Dec 2025 | 9,740,063 | +9.9% | 4.12 | |
| 28 Nov 2025 | 8,865,578 | -14.1% | 3.31 | |
| 14 Nov 2025 | 10,321,719 | -1.7% | 2.03 |
FINRA consolidated short interest, reported twice a month for every US listing.
Avidity Biosciences IncのSEC提出書類と決算説明会の議事録
What recent news says about Avidity Biosciences Inc, scored for sentiment.